Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Optimization of Infliximab in Psoriasis
NCT00833053Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2009
- Primary completion
- Apr 2011
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of infliximab in plaque psoriasis, sponsored by Merck & Co.. Started Oct 2009; status: terminated.
02
Drugs
infliximab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00833053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00833053.